CD8A and neoplasm: Systemic administration of this formulation enabled preferential accumulation in both tumor tissue and key immune organs, including the spleen, and was associated with increased CD8 + T-cell infiltration into the TME, indicative of a potential transition from cold to hot tumor phenotypes.